Gelteq (GELS) Competitors $1.82 +0.00 (+0.01%) As of 11:21 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOwnershipSEC FilingsTrendsBuy This Stock GELS vs. IMMX, BMEA, GANX, RENB, DTIL, IKNA, FBRX, VRCA, RNTX, and BLUEShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Immix Biopharma (IMMX), Biomea Fusion (BMEA), Gain Therapeutics (GANX), Renovaro (RENB), Precision BioSciences (DTIL), Ikena Oncology (IKNA), Forte Biosciences (FBRX), Verrica Pharmaceuticals (VRCA), Rein Therapeutics (RNTX), and bluebird bio (BLUE). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Immix Biopharma Biomea Fusion Gain Therapeutics Renovaro Precision BioSciences Ikena Oncology Forte Biosciences Verrica Pharmaceuticals Rein Therapeutics bluebird bio Immix Biopharma (NASDAQ:IMMX) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership. Does the MarketBeat Community prefer IMMX or GELS? Immix Biopharma received 11 more outperform votes than Gelteq when rated by MarketBeat users. CompanyUnderperformOutperformImmix BiopharmaOutperform Votes11100.00% Underperform VotesNo VotesGelteqN/AN/A Which has higher earnings and valuation, IMMX or GELS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$15.43M-$0.70-3.43GelteqN/AN/AN/AN/AN/A Do insiders and institutionals hold more shares of IMMX or GELS? 11.3% of Immix Biopharma shares are held by institutional investors. 55.4% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is IMMX or GELS more profitable? Gelteq's return on equity of 0.00% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -102.68% -80.89% Gelteq N/A N/A N/A Do analysts rate IMMX or GELS? Immix Biopharma currently has a consensus target price of $7.00, suggesting a potential upside of 191.67%. Given Immix Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Immix Biopharma is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to IMMX or GELS? In the previous week, Immix Biopharma had 1 more articles in the media than Gelteq. MarketBeat recorded 2 mentions for Immix Biopharma and 1 mentions for Gelteq. Immix Biopharma's average media sentiment score of 0.00 equaled Gelteq'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gelteq 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryImmix Biopharma beats Gelteq on 7 of the 9 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.18M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E RatioN/A9.0426.7819.69Price / SalesN/A253.23386.97118.34Price / CashN/A65.8538.2534.62Price / BookN/A6.406.744.50Net IncomeN/A$143.98M$3.23B$248.32M7 Day Performance8.34%1.90%1.49%-0.03%1 Month Performance-36.80%4.01%11.47%12.72%1 Year PerformanceN/A-3.00%16.57%7.38% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.82+0.0%N/AN/A$17.18MN/A0.00N/AGap DownIMMXImmix Biopharma1.953 of 5 stars$1.98flat$7.00+253.5%-9.1%$55.11MN/A-2.339News CoverageBMEABiomea Fusion2.6832 of 5 stars$1.46-10.4%$22.60+1,447.9%-87.5%$54.86MN/A-0.3650GANXGain Therapeutics1.9843 of 5 stars$1.86-3.6%$8.20+340.9%-27.6%$54.73M$50,000.00-1.6920News CoverageAnalyst ForecastAnalyst RevisionRENBRenovaro0.8116 of 5 stars$0.33-1.6%N/A-69.9%$52.38MN/A-0.3520Gap UpDTILPrecision BioSciences3.4762 of 5 stars$4.95-3.7%$47.00+849.5%-64.4%$52.22M$68.70M82.51200Earnings ReportAnalyst ForecastIKNAIkena Oncology2.8393 of 5 stars$1.08-6.9%$3.00+177.8%-16.7%$52.12M$659,000.00-0.8870Positive NewsFBRXForte Biosciences2.639 of 5 stars$7.60+11.8%$32.50+327.6%+30,134.7%$50.03MN/A-0.475News CoverageEarnings ReportGap UpVRCAVerrica Pharmaceuticals4.2326 of 5 stars$0.54-2.7%$8.00+1,394.5%-92.7%$49.49M$7.57M-0.2940Analyst RevisionGap DownRNTXRein TherapeuticsN/A$2.25+14.8%N/AN/A$49.48MN/A-0.729Earnings ReportGap DownHigh Trading VolumeBLUEbluebird bio2.705 of 5 stars$4.98+50.5%$44.60+795.6%-75.1%$48.75M$83.81M-0.13520High Trading Volume Related Companies and Tools Related Companies Immix Biopharma Competitors Biomea Fusion Competitors Gain Therapeutics Competitors Renovaro Competitors Precision BioSciences Competitors Ikena Oncology Competitors Forte Biosciences Competitors Verrica Pharmaceuticals Competitors Rein Therapeutics Competitors bluebird bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
